Kebilidi (eladocagene exuparvovec-tneq) – New orphan drug approval
November 14, 2024 - The FDA announced the approval of PTC Therapeutics’ Kebilidi (eladocagene exuparvovec-tneq), for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency.
Download PDF
